SG11201607795UA - Inos-inhibitory compositions and their use as breast cancer therapeutics - Google Patents

Inos-inhibitory compositions and their use as breast cancer therapeutics

Info

Publication number
SG11201607795UA
SG11201607795UA SG11201607795UA SG11201607795UA SG11201607795UA SG 11201607795U A SG11201607795U A SG 11201607795UA SG 11201607795U A SG11201607795U A SG 11201607795UA SG 11201607795U A SG11201607795U A SG 11201607795UA SG 11201607795U A SG11201607795U A SG 11201607795UA
Authority
SG
Singapore
Prior art keywords
inos
breast cancer
cancer therapeutics
inhibitory compositions
inhibitory
Prior art date
Application number
SG11201607795UA
Inventor
Jenny Chee Ning Chang
Original Assignee
Methodist Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methodist Hospital filed Critical Methodist Hospital
Publication of SG11201607795UA publication Critical patent/SG11201607795UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11201607795UA 2014-04-08 2015-04-08 Inos-inhibitory compositions and their use as breast cancer therapeutics SG11201607795UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461976956P 2014-04-08 2014-04-08
PCT/US2015/025009 WO2015157471A1 (en) 2014-04-08 2015-04-08 Inos-inhibitory compositions and their use as breast cancer therapeutics

Publications (1)

Publication Number Publication Date
SG11201607795UA true SG11201607795UA (en) 2016-10-28

Family

ID=53008865

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607795UA SG11201607795UA (en) 2014-04-08 2015-04-08 Inos-inhibitory compositions and their use as breast cancer therapeutics

Country Status (9)

Country Link
US (4) US20170020835A1 (en)
EP (2) EP3967303A1 (en)
JP (4) JP2017515800A (en)
KR (1) KR20160143775A (en)
CN (1) CN106572988B (en)
AU (1) AU2015243537B2 (en)
CA (1) CA2979530C (en)
SG (1) SG11201607795UA (en)
WO (1) WO2015157471A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5836940B2 (en) 2009-06-26 2015-12-24 ソリシメド・バイオファーマ・インコーポレーテッド Soricidin derived peptides and methods for detection and drug delivery of TRPV-6 cancer
SG11201607795UA (en) * 2014-04-08 2016-10-28 Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics
JP6539345B2 (en) * 2014-10-24 2019-07-03 朗齊生物医学股▲分▼有限公司 Use of duloxetine hydrochloride drug in the preparation of a pharmaceutical composition for the treatment of cancer
IL292946A (en) 2016-03-02 2022-07-01 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
WO2017163243A1 (en) * 2016-03-22 2017-09-28 Hadasit Medical Research Services And Development Ltd. Modulation of calcium channel splice variant in cancer therapy
WO2018071837A1 (en) * 2016-10-14 2018-04-19 Baylor College Of Medicine Radiofrequency field hyperthermia and solid tumor immunomodulation
EP3648764A4 (en) * 2017-07-03 2021-03-31 Menri Group Ltd. Treatment of cancer with dihydropyridines
WO2019060613A2 (en) * 2017-09-22 2019-03-28 John Mansell Compositions and methods for treatment of sepsis-related disorders
JP2021505659A (en) * 2017-12-01 2021-02-18 ソリシメド バイオファーマ インコーポレイテッド TRPV6 Inhibitors and Combination Therapies for Cancer Treatment
WO2019147089A1 (en) * 2018-01-26 2019-08-01 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for preventing or treating cancer comprising, as active ingredient, calcium channel inhibitor or pharmaceutically acceptable salt thereof
KR102212699B1 (en) 2019-08-12 2021-02-05 한국원자력의학원 Composition for the prevention or treatment of breast cancer
CN113897357A (en) * 2020-07-06 2022-01-07 北京大学 Twist1 gene editing system and application thereof in preparation of product for treating triple negative breast cancer
WO2024063566A1 (en) * 2022-09-22 2024-03-28 (의) 삼성의료재단 Pharmaceutical composition for destruction of tumor blood vessels
WO2024063569A1 (en) * 2022-09-22 2024-03-28 (의) 삼성의료재단 Pharmaceutical composition for disrupting tumor blood vessels

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121152A1 (en) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "USE OF THE COMBINATION OF AN AROMATASE INHIBITOR WITH AN ANTIANDROGEN FOR PROPHYLAXIS AND THERAPY OF PROSTATE HYPERPLASIA"
US4658957A (en) * 1985-01-28 1987-04-21 Abbott Laboratories Utility tray
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5747532A (en) 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
GB9625895D0 (en) 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
JP2002511868A (en) 1997-06-30 2002-04-16 アラーガン・セイルズ・インコーポレイテッド Calcium blockers for treating proliferative vitreoretinopathy
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US8431117B2 (en) 1999-08-30 2013-04-30 David S Terman Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
CA2478145A1 (en) * 2002-03-06 2003-09-12 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics in cancer treatment
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
WO2005082407A1 (en) 2003-11-03 2005-09-09 Musc Foundation For Research Development Use of quercetin and resveratrol to treat and prevent oral cancer
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1817030A2 (en) 2004-12-01 2007-08-15 Kalypsys, Inc. Inducible nitric oxide synthase dimerization inhibitors
CA2597247A1 (en) * 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
WO2007101213A2 (en) 2006-02-28 2007-09-07 Kalypsys, Inc. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
WO2007123777A2 (en) * 2006-03-30 2007-11-01 Duke University Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
US20080069904A1 (en) 2006-07-18 2008-03-20 Oronsky Bryan T Inhibition of angiogenesis through nitric oxide tachyphylaxis
WO2008046459A1 (en) 2006-10-16 2008-04-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule
WO2008103615A1 (en) 2007-02-21 2008-08-28 Kalypsys, Inc. Isoquinolines useful as inducible nitric oxide synthase inhibitors
TW200924772A (en) 2007-08-27 2009-06-16 Kalypsys Inc Heterobicyclic-substituted quinolones useful as nitric oxide synthase inhibitors
US20110195935A1 (en) * 2008-09-24 2011-08-11 Michael Farber Nitric oxide releasing amino acid ester compound, composition and method of use
WO2011032000A2 (en) * 2009-09-10 2011-03-17 New York University Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide
MX2014001221A (en) * 2011-08-02 2014-03-27 Astellas Pharma Inc Method for treating cancer by combined use of medicinal agents.
SG11201607795UA (en) * 2014-04-08 2016-10-28 Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics

Also Published As

Publication number Publication date
CN106572988A (en) 2017-04-19
US20200016265A1 (en) 2020-01-16
US11357850B2 (en) 2022-06-14
CA2979530C (en) 2023-10-03
US10420838B2 (en) 2019-09-24
KR20160143775A (en) 2016-12-14
JP2017515800A (en) 2017-06-15
CA2979530A1 (en) 2015-10-15
JP2020128446A (en) 2020-08-27
JP2022159552A (en) 2022-10-17
US20170020835A1 (en) 2017-01-26
EP3129015A1 (en) 2017-02-15
EP3967303A1 (en) 2022-03-16
AU2015243537B2 (en) 2020-10-22
US20200306371A1 (en) 2020-10-01
JP2020128445A (en) 2020-08-27
US20170224814A1 (en) 2017-08-10
CN106572988B (en) 2022-04-08
AU2015243537A1 (en) 2016-10-06
EP3129015B1 (en) 2021-07-14
WO2015157471A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
SG11201607795UA (en) Inos-inhibitory compositions and their use as breast cancer therapeutics
GB201411197D0 (en) Composition and use thereof
HK1232137A1 (en) Therapeutic compounds and compositions
PT3015526T (en) Halo-olefin composition and use therefor
IL250568A0 (en) Anti-methanogenic compositions and uses thereof
EP3186393A4 (en) Methods and compositions related to prostate cancer therapeutics
ZA201701909B (en) Trichoderma compositions and methods of use
IL250582B (en) Compositions and methods for therapeutics prescreening
IL276733A (en) Use of eribulin in the treatment of cancer
EP3008124A4 (en) Starch compositions and use thereof
IL255560A (en) Macropinocytosis in cancer
HK1231426A1 (en) Skin-brightening cosmetic composition
GB2537548B (en) Set-delayed cement compositions comprising pumice and associated methods
IL251238B (en) Mineral based compositions and use thereof
GB201411196D0 (en) Composition and use thereof
IL248126A0 (en) Combination of cancer therapeutics
GB201408233D0 (en) Use of polyanionic composition
GB201522573D0 (en) Cancer therapeutics
GB201503273D0 (en) Cancer therapeutics
GB201404391D0 (en) Novel compositions having use in therapy
GB201500760D0 (en) Cancer therapeutics
GB201502816D0 (en) Novel Compositions having use in therapy
ZA201403006B (en) Composition for use in treatment of cancer
GB201418410D0 (en) use of compositions of matter
GB201410695D0 (en) Uses of oligouronates in cancer treatment